Jazz Pharmaceuticals

135.41
-6.61 (-4.65%)
At close: Mar 25, 2025, 3:59 PM
135.32
-0.06%
Pre-market: Mar 26, 2025, 07:23 AM EDT
-4.65%
Bid 134.6
Market Cap 8.22B
Revenue (ttm) 4.08B
Net Income (ttm) 561.92M
EPS (ttm) 8.65
PE Ratio (ttm) 15.65
Forward PE 5.65
Analyst Buy
Ask 137.99
Volume 1,110,200
Avg. Volume (20D) 825,532
Open 141.59
Previous Close 142.02
Day's Range 133.90 - 142.07
52-Week Range 99.06 - 148.06
Beta 0.44

About JAZZ

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include ...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 1, 2007
Employees 2,800
Stock Exchange NASDAQ
Ticker Symbol JAZZ
Full Company Profile

Analyst Forecast

According to 13 analyst ratings, the average rating for JAZZ stock is "Buy." The 12-month stock price forecast is $179, which is an increase of 32.20% from the latest price.

Stock Forecasts

Next Earnings Release

Jazz Pharmaceuticals is scheduled to release its earnings on Apr 30, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
4 weeks ago
+3.22%
Jazz Pharmaceuticals shares are trading higher aft... Unlock content with Pro Subscription
1 month ago
+1.02%
Jazz Pharmaceuticals shares are trading higher after Wells Fargo upgraded the stock from Equal-Weight to Overweight and raised its price target from $130 to $170.